401
CHAPTER 15 ■ Schizophrenia Spectrum and Other Psychotic Disorders
A meta-analysis of longitudinal data. Psychological Medicine, 45 , 1613-1627. https://doi.org/10.1017/S0033291714002712 Shrivastava, A., Shah, N., Johnston, M., Stitt, L., & Thakar, M. (2010). Predictors of long-term outcome of first-episode schizophrenia: A ten-year follow-up study. Indian Jour- nal of Psychiatry, 52 (4), 320–326. https://doi.org/10.4103 /0019-5545.74306 Stahl, S. M. (2013). Stahl’s essential psychopharmacology: Neuroscien- tific basis and practical applications (4th ed.). Cambridge Univer- sity Press. Stroup, T. S., Olfson, M., Huang, C., Wall, M. M., Goldberg, T., Devanand, D. P., & Gerhard, T. P. (2021). Age-specific preva- lence and incidence of dementia diagnoses among older us adults with schizophrenia. JAMA Psychiatry, 78 (6), 632–641. https://doi.org/10.1001/jamapsychiatry.2021.0042 Takeuchi, H., Kantor, N., Sanches, M., Fervaha, G., Agid, O., & Remington, G. (2017). One-year symptom trajectories in patients with stable schizophrenia maintained on anti psychotics versus placebo: Meta-analysis. British Journal of Psychiatry, 211 (3). https://doi.org/10.1192/bjp.bp.116 .186007 Thunè, H., Recasens, M., & Uhlhaas, P. J. (2016). The 40-Hz auditory steady-state response in patients with schizophre- nia: A meta-analysis. JAMA Psychiatry, 78(11), 1145–1153 . http://jamanetwork.com/journals/jamapsychiatry/article -abstract/2566207 Tripathi, A., Kar, S. K., & Shukla, R. (2018). Cognitive deficits in schizophrenia: Understanding the biological correlates and remediation strategies. Clinical Psychopharmacology and Neuroscience, 16 (1), 7–17. https://doi.org/10.9758/cpn.2018 .16.1.7 Urvakhsh, M. M., Thirthalli, J., Aneelraj, D., Jadhav, P., Gan- gadhar, B. N., & Keshavan, M. S. (2014). Mirror neuron dys- function in schizophrenia and its functional implications: A systematic review. Schizophrenia Research, 160 (1–3), 9–19.
https://doi.org/http://dx.doi.org/10.1016/j.schres.2014 .10.040 Veijola, J., Guo, J. Y., Moilanen, J. S., Jaaskelainen, E., Miettunen, J., Kyllonen, M., Haapea, M., Huhtaniska, S., Alaräisänen, A., Mäki, P., Kiviniemi, V., Nikkinen, J., Starck, T., Remes, J. J., Tanskanen, P., Tervonen, O., Wink, A. M., Kehagia, A., Suckling, J., . . . Murray, G. (2014). Longitudinal changes in total brain volume in schizophrenia: Relation to symptom sever- ity, cognition and antipsychotic medication. PLoS ONE, 9 (7), e101689. https://doi.org/10.1371/journal.pone.0101689 Viher, P. V., Stegmayer, K., Giezendanner, S., Federspiel, A., Bohlhalter, S., Vanbellingen, T., Weist, R., Strik, W., & Walthera, S. (2016). Cerebral white matter structure is associated with DSM-5 schizophrenia symptom dimensions. Neu- roimage: Clinical, 12 (Suppl. 7), 93–99. https://doi.org/10.1016 /j.nicl.2016.06.013 Waters, F., Collerton, D., Ffytche, D. H., Jardri, R., Pins, D., Dudley, R., Blom, J. D., Mosimann, U. P., Eperjesi, F., Ford, S., & Laroi, F. (2014). Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease. Schizophrenia Bulletin, 40 (Suppl. 4), 233–245. https://doi.org/10.1093/schbul/sbu036 Weiden, P. J. (2010). Is recovery attainable in schizophrenia? Med- scape Psychiatry & Mental Health. http://www.medscape.com /viewarticle/729750 Wu, Q., Gilbody, S., Peckham, E., Brabyn, S., & Parrott, S. (2016). Varenicline for smoking cessation and reduction in people with severe mental illnesses: Systematic review and meta- analysis. Addiction, 111 (9), 1554–1567. Advance online publi- cation. https://doi.org/10.1111/add.13415 Classical Reference Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and neg- ative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13 (2), 261–276.
Powered by FlippingBook